Aurobindo Pharma · NSE: AUROPHARMA · BSE: 524804

Q2 FY20 results · Jul–Sep 2019

Aurobindo Pharma reported revenue from operations of ₹5,600.47 crore (up 17.9% from Q2 FY19) and net profit of ₹639.53 crore (up 4.6% from Q2 FY19) for Q2 FY20 (Jul–Sep 2019), on a consolidated basis.

Consolidated · ₹ crore
Item	Q2 FY20	Q2 FY19	YoY	Q1 FY20	QoQ
Revenue from operations	5,600.47	4,751.40	+17.9%	5,444.60	+2.9%
Other income	20.62	26.26	−21.5%	15.78	+30.7%
Total income	5,621.09	4,777.66	+17.7%	5,460.38	+2.9%
Profit before share of associates & JVs and tax	863.83	786.62	+9.8%	858.73	+0.6%
Share of profit/(loss) of associates & JVs	0.07	0.24		4.71
Net profit for the period	639.53	611.44	+4.6%	635.68	+0.6%
Attributable to shareholders of the company	639.86	803.06	−20.3%	635.83	+0.6%
EPS, basic (₹)	10.92	10.44	+4.6%	10.85	+0.6%
Net margin (%)	11.4	12.9		11.7

This company reports a share of profit/(loss) from associates and joint ventures. BSE’s filing format records that share after tax, so it is shown on its own line. The company’s own statement may add it before its “profit before tax” line.

Standalone · ₹ crore
Item	Q2 FY20	Q2 FY19	YoY	Q1 FY20	QoQ
Revenue from operations	3,221.66	3,170.39	+1.6%	3,078.83	+4.6%
Other income	33.64	4.18	+704.8%	30.14	+11.6%
Total income	3,255.30	3,174.57	+2.5%	3,108.97	+4.7%
Profit before tax	522.06	479.41	+8.9%	433.45	+20.4%
Net profit for the period	398.13	380.95	+4.5%	330.50	+20.5%
EPS, basic (₹)	6.80	6.50	+4.6%	5.64	+20.6%
Net margin (%)	12.4	12.0		10.7

Consolidated

Filed with BSE: 13 Nov 2019, 17:43 IST
Board meeting: 12 Nov 2019
Period: 01 Jul 2019 to 30 Sep 2019
Review status: Unaudited
Source: XBRL filing on BSE

Standalone

Filed with BSE: 13 Nov 2019, 17:43 IST
Board meeting: 12 Nov 2019
Period: 01 Jul 2019 to 30 Sep 2019
Review status: Unaudited
Source: XBRL filing on BSE